Rasuvo methotrexate regulatory update

FDA approved an NDA for Rasuvo methotrexate - an autopen containing subcutaneous injectable methotrexate - to manage severe, active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis (pJIA)

Read the full 279 word article

How to gain access

Continue reading with a
two-week free trial.